efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 34 Diseases   9 Trials   9 Trials   673 News 


«12345678»
  • ||||||||||  BIT 225 / Biotron
    [VIRTUAL] PHASE II TRIAL OF VPU INHIBITOR BIT225 IN COMBINATION WITH ANTIRETROVIRAL THERAPY ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_1221;    
    Vpu has been associated with reducing cell surface expression/function of numerous cellular proteins/receptors involved in viral antigen presentation to CD4+, CD8+ T cells and NK cells. The production of IL-21 by Tfh, Th17, and/or NK cells is a unique immunological consequence of addition of BIT225 to ART and offers the potential for treatment targeting different HIV-1 compartments during standard therapy.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    [VIRTUAL] SAFETY AND EFFICACY OF DTG VS EFV AND TDF VS TAF IN PREGNANCY: IMPAACT 2010 TRIAL ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_323;    
    Pregnant women with HIV-1 in 9 countries were randomized 1:1:1 to start open-label DTG+FTC/TAF, DTG+FTC/TDF, or EFV/FTC/TDF at 14-28 weeks gestational age (GA)...DTG+FTC/TAF had the lowest composite frequency of adverse pregnancy outcomes. Maternal and infant AE outcomes were similar by arm.
  • ||||||||||  lamivudine / Generic mfg.
    Retrospective data, Journal, Adverse drug reaction:  Nature and prevalence of adverse drug reaction of antiretroviral medications in Halibet National Referral Hospital: a retrospective study. (Pubmed Central) -  Jan 31, 2020   
    Furthermore, CD4 count below 200, was identified as a major risk factor that predisposes patients to ADRs. This is burdensome to resource constrained countries such as Eritrea who have limited drug options and high HIV prevalence, therefore these findings will help patients and healthcare professionals understand the nature as well as seriousness of these ADRs and identify the risks involved with ART medications which can help minimize ART associated ADRs early on.
  • ||||||||||  Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, NN1213 / Novo Nordisk
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) -  Jan 15, 2020   
    P4,  N=223, Active, not recruiting, 
    This is burdensome to resource constrained countries such as Eritrea who have limited drug options and high HIV prevalence, therefore these findings will help patients and healthcare professionals understand the nature as well as seriousness of these ADRs and identify the risks involved with ART medications which can help minimize ART associated ADRs early on. Recruiting --> Active, not recruiting | N=150 --> 223 | Trial completion date: Aug 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Mar 2019
  • ||||||||||  efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., etoposide IV / Generic mfg.
    Trial completion, Trial completion date:  REACT-KS: Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma (clinicaltrials.gov) -  Nov 15, 2019   
    P3,  N=192, Completed, 
    The impact of comedications containing only strong CYP3A4 inhibitors e.g. ritonavir was less pronounced, suggesting benefit of riociguat over PAH-targeting medications with contraindications for use with strong CYP3A4 inhibitors. Active, not recruiting --> Completed | Trial completion date: Sep 2019 --> Nov 2018
  • ||||||||||  Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) / Gilead, BMS, Isentress (raltegravir) / Merck (MSD), azathioprine orodispersible / Generic Mfg.
    Autoantibodies, drugs and a failing liver (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_2150;    
    He started Atripla and within three months VL was < 40 and CD4 524(27%)...His Rilpivirine was switched to Raltegravir and a liver screen repeated (table 1)...He commenced prednisolone initially, later azathioprine...· Due to the overlap between these conditions it is essential that in cases of hepatic impairment medications are reviewed and any potentially causative or triggering agents are withdrawn. [Serum ALT] [Liver histology]
  • ||||||||||  Prezista (darunavir) / J&J, Pifeltro (doravirine) / Merck (MSD), lamivudine / Generic Mfg.
    Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1696;    
    Although women had similar efficacy and safety results, women represented 15% of participants. Increased enrollment of women in clinical trials or women-only trials should be considered to further understand antiretroviral efficacy and safety in this important population.
  • ||||||||||  Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) / Gilead, BMS, Isentress (raltegravir) / Merck (MSD), azathioprine orodispersible / Generic Mfg.
    Autoantibodies, drugs and a failing liver (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1373;    
    He started Atripla and within three months VL was < 40 and CD4 524(27%)...His Rilpivirine was switched to Raltegravir and a liver screen repeated (table 1)...He commenced prednisolone initially, later azathioprine...· Due to the overlap between these conditions it is essential that in cases of hepatic impairment medications are reviewed and any potentially causative or triggering agents are withdrawn. [Serum ALT] [Liver histology]
  • ||||||||||  Prezista (darunavir) / J&J, Pifeltro (doravirine) / Merck (MSD), lamivudine / Generic Mfg.
    Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_886;    
    Although women had similar efficacy and safety results, women represented 15% of participants. Increased enrollment of women in clinical trials or women-only trials should be considered to further understand antiretroviral efficacy and safety in this important population.
  • ||||||||||  Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) / Gilead, BMS, Isentress (raltegravir) / Merck (MSD), azathioprine orodispersible / Generic Mfg.
    Autoantibodies, drugs and a failing liver (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_211;    
    He started Atripla and within three months VL was < 40 and CD4 524(27%)...His Rilpivirine was switched to Raltegravir and a liver screen repeated (table 1)...He commenced prednisolone initially, later azathioprine...· Due to the overlap between these conditions it is essential that in cases of hepatic impairment medications are reviewed and any potentially causative or triggering agents are withdrawn. [Serum ALT] [Liver histology]
  • ||||||||||  Prezista (darunavir) / J&J, Pifeltro (doravirine) / Merck (MSD), lamivudine / Generic Mfg.
    Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_138;    
    Although women had similar efficacy and safety results, women represented 15% of participants. Increased enrollment of women in clinical trials or women-only trials should be considered to further understand antiretroviral efficacy and safety in this important population.
  • ||||||||||  Clinical, Journal:  Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted HIV Antiretroviral Regimens in Healthy Volunteers. (Pubmed Central) -  Nov 6, 2019   
    SOF/VEL and ARV regimens were administered alone and in combination; ARVs (and pharmacokinetic enhancers) included atazanavir (ATV), cobicistat (COBI), darunavir (DRV), dolutegravir (DTG), efavirenz (EFV), elvitegravir (EVG), emtricitabine (FTC), lopinavir (LPV), raltegravir (RAL), rilpivirine (RPV), ritonavir (RTV), tenofovir alafenamide (TAF), and tenofovir disoproxil fumarate (TDF)...No clinically relevant differences in the pharmacokinetics (PK) of SOF, SOF metabolite GS-331007, or VEL were observed other than an approximate 50% decrease in VEL exposure when administered with EFV/FTC/TDF...SOF/VEL and ARV regimens including ATV, COBI, DRV, DTG, EVG, FTC, LPV, RAL, RPV, RTV, TAF, or TDF may be coadministered without dose adjustment. Use of SOF/VEL with EFV-containing regimens is not recommended due to ~50% reduction in VEL exposure.
  • ||||||||||  Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
    Trial completion date:  Effects of Switching From ATRIPLA (clinicaltrials.gov) -  Aug 29, 2019   
    P2b,  N=86, Active, not recruiting, 
    Two years of lopinavir/r monotherapy had no deleterious clinical impact when compared with EFV/FTC/TDF. Trial completion date: Jun 2020 --> May 2022
  • ||||||||||  tenofovir disoproxil fumarate / Generic Mfg., Atripla (efavirenz+emtricitabine+tenofovir) / Gilead, BMS
    Journal:  3D Printed, Controlled Release, Tritherapeutic Tablet Matrix for Advanced Anti-HIV-1 Drug Delivery. (Pubmed Central) -  Aug 17, 2019   
    A 3DP FDC was successfully manufactured with the aid of a 3D-Bioplotter in a single step process. The versatile HA-PQ10 entrapped all drugs and achieved an enhanced relative bioavailability of EFV, TDF, and FTC compared to the market formulation for potentially enhanced HIV treatment.
  • ||||||||||  Atripla (efavirenz+emtricitabine+tenofovir) / Gilead, BMS
    Journal:  Trends in ART Prescription, Durability and Modification: New drugs, more changes, but less failure. (Pubmed Central) -  Jul 24, 2019   
    In treatment-naive PLWH, NNRTI and InSTI-based ART were most durable, relative to PI and InSTI/PI-based ART, and were least likely to be modified/discontinued. A greater understanding of reasons for regimen modification/discontinuation is needed to analyze contemporary regimen durability.